The Christie Foundation Trust Annual Report and Accounts 2021-22

Research

• A Phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08) (Mairead McNamara, The Oncologist) • Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) (Adam Gibb, British Journal of Haematology) • Second-line FOLFOX Advanced biliary tract cancer 2L phase III trial (Angela Lamarca, Lancet Oncology) In 2021, The Christie clinical research community continued to drive a programme of clinically relevant and practice changing studies despite the challenges of COVID-19. Their focus and dedication was exemplified in the receipt of multiple awards at the NW region CRN / GM cancer awards November 2020. We acknowledge and thank all the patients, their families and the public who have contributed to our research during the past year.

26